Summit Securities Group’s Oruka Therapeutics ORKA Stock Holding History

Summit Securities Group’s Portfolio ORKA Stock Details ORKA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$12.6K	Buy	+151	New	+$14.2K	﹤0.01%	775

Other funds holding ORKA

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $109B AUM 51.53% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Summit Securities Group's ORKA Position: Q3 2026 in Review

Summit Securities Group opened a new position in Oruka Therapeutics (ORKA) in Q3 2026: 151 shares worth $12.6K. The stake represents ﹤0.01% of the portfolio and ranks #775 among its holdings.

102 funds tracked by Wall St. Rank hold ORKA as of Q3 2026.

Summit Securities Group held 151 shares of Oruka Therapeutics worth $12.6K as of Q3 2026.
Oruka Therapeutics was a new Summit Securities Group position in Q3 2026.
Oruka Therapeutics made up ﹤0.01% of Summit Securities Group's portfolio in Q3 2026, its #775 holding.
102 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q3 2026.

Based on Summit Securities Group's 13F filing for Q3 2026, filed 5 Nov 2026.